Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1248-1257, Vol. 8, No. 6
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.6.1248-1257.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Enzyme-Linked Immunospot Assays Provide a Sensitive
Tool for Detection of Cytokine Secretion by Monocytes
Mathilde
Kouwenhoven,*
Volkan
Özenci,
Natalia
Teleshova,
Yassir
Hussein,
Yu-Min
Huang,
Alexandre
Eusebio, and
Hans
Link
Neuroimmunology Unit, Division of Neurology,
Karolinska Institute, Huddinge University Hospital, Stockholm,
Sweden
Received 12 April 2001/Returned for modification 23 May
2001/Accepted 27 July 2001
 |
ABSTRACT |
Blood monocytes as well as tissue-differentiated macrophages play a
pivotal role in controlling immune reactions. Monocytes regulate the
extent, nature, and duration of immune responses by secretion of
cytokines. Interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-
),
IL-10, and IL-12 are of particular interest, since IL-12 shifts the
immune response towards a Th1 type, facilitating the production of,
e.g., TNF-
and IL-6, while IL-10 counteracts Th1 responses and
promotes the production of Th2-related cytokines such as IL-4. A tight
regulation of these four cytokines keeps the balance and decides
whether Th1 or Th2 will predominate in immune reactions. Enzyme-linked
immunospot (ELISPOT) assays are among the most-sensitive and -specific
methods available for cytokine research. They permit ex vivo
identification of individual cells actively secreting cytokines. In the
present study we prepared monocytes from healthy subjects' blood and
adapted ELISPOT assays to define optimal conditions to detect and
enumerate monocytes secreting IL-6, TNF-
, IL-10, and IL-12. The
optimal time for monocyte incubation was 24 h, and optimal
monocyte numbers (in cells per well) were 2,000 for IL-6, 1,000 for
TNF-
, 50,000 for IL-10, and 100,000 for enumeration of IL-12
secreting monocytes. Among healthy subjects, 10% ± 5% of the
monocytes secreted IL-6, 12% ± 12% secreted TNF-
, 0.1% ± 0.1%
secreted IL-10, and 0.2% ± 0.3% secreted IL-12 (values are
means ± standard deviations). In conclusion, ELISPOT
assays constitute a valuable tool to enumerate monocytes secreting
IL-6, TNF-
, IL-10, and IL-12 and probably to enumerate monocytes
secreting other cytokines and proteins.
 |
INTRODUCTION |
Blood monocytes and
tissue-differentiated macrophages play a pivotal role in specific as
well as nonspecific immune reactions (4, 10).
Monocytes/macrophages act as scavengers of invading microorganisms,
presenters of antigens to T cells, and secretors of many
immunoregulatory cytokines (11, 18).
Monocytes regulate the immune response through the secretion of
cytokines. These secreted cytokines play a critical role in determining
the extent, nature, and duration of immune responses. The study of
monocytes prepared from biological fluids and their cytokine profile
reflected by cytokine secretion has the potential to evaluate monocyte
functions in physiological situations and disease states, e.g., prior
to their activation and recruitment into tissue (29, 30).
Measurements of cytokines are not without problems. This might be
reflected by the variety of techniques commonly used to measure
cytokines, such as reverse transcription-PCR, in situ hybridization, enzyme-linked immunosorbent assays (ELISA), flow cytometry and enzyme-linked immunospot (ELISPOT) assays. ELISA is
mostly used to measure cytokines in body fluids. The presence of
cytokine binding proteins in body fluids may reduce the biological relevance of cytokine measurement by ELISA (3). Certain
cytokines are difficult to detect in serum (1, 16) due to
their short half-life, and rapid uptake/utilization in particular at
sites of production (2). In situ hybridization
(17) and reverse transcription-PCR (28) allow
measurements of cytokine mRNA expression in isolated cell populations.
mRNA levels, though, do not necessarily reflect protein levels.
Combining cell surface and cytoplasmic staining in flow
cytometry, synthesized cytokine can be identified. However, for many
cytokines this requires in vitro stimulation of the isolated cells
(2). Furthermore, flow cytometry detects synthesized but
not necessarily secreted cytokines.
ELISPOT assays circumvent many of these limitations. ELISPOT assays
permit the ex vivo identification of cells actively secreting cytokines. Furthermore, ELISPOT assays are highly efficient (when using
gene transfectants, 100% of cells can be detected) and fast. ELISPOT
assays can detect a single cell out of a million, each cell releasing
less than 100 molecules of a certain cytokine per second
(24). High specificity combined with a sensitivity up to
200 times higher than that of conventional ELISAs (27) may make ELISPOT assays an attractive tool for the detection and
enumeration of cytokine secreting monocytes. Drawbacks of ELISPOT
assays are that phenotyping of cells secreting cytokines is difficult
to perform in parallel, the amount of secreted cytokine per cell cannot
be quantified, and the method may be relatively expensive.
In this study we used a modified two-step density gradient method to
obtain monocytes of high purity from blood. The aim of this study was
to adapt ELISPOT assays to detect and enumerate monocytes secreting
interleukin 6 (IL-6), IL-10, IL-12, and tumor necrosis factor alpha
(TNF-
).
 |
MATERIALS AND METHODS |
Donors.
Blood specimens were obtained from 49 healthy
subjects (25 females) with a mean age ± standard deviation of
43 ± 12 years, consisting of staff from the Neuroimmunology
Department and blood donors.
Antibodies and cytokines.
Monoclonal antibodies (MAb)
to human IL-6, IL-10, and IL-12p40 and biotinylated MAb to human IL-6,
IL-10, and IL-12p40 were all from Mabtech (Stockholm, Sweden), and MAb
to TNF-
and biotinylated polyclonal antibody to TNF-
were from
R&D Systems (R&D Systems, Oxon, United Kingdom).
Peridinin chlorophyll protein-labeled MAb to CD3; phycoerythrin
(PE)-labeled MAb to CD14, CD80, CD86, HLA-ABC, and HLA-DR; fluorescein
isothiocyanate (FITC)-labeled MAb to CD15, CD19, and CD56 were obtained
from Becton Dickinson (Mountain View, Calif.). PE-labeled MAb to CD40
was from Serotec (Oxford, United Kingdom). FITC-labeled MAb to CD14 and
irrelevant isotype-matched MAb were PE-immunoglobulin G1 (IgG1) and
FITC-IgG1 from Dako (Copenhagen, Denmark).
Preparation of MNC.
Blood mononuclear cells (MNC) were
separated by density gradient centrifugation on Lymphoprep (Nycomed,
Oslo, Norway). Cells from the interphase were collected, washed three
times with Dulbecco's modification of Eagle's medium (Gibco, Paisley,
United Kingdom) and supplemented with antibiotics, 10% fetal calf
serum (Gibco), 1% minimal essential medium (Gibco), and 1%
L-glutamine (Gibco). Cells were adjusted to a concentration
of 106 cells/ml. Cell viability as measured by
trypan blue exclusion always exceeded 95%.
Preparation of monocytes.
Percoll (Pharmacia, Uppsala,
Sweden) separation (6, 14) with modifications was used to
prepare monocytes from blood. A total of 20 × 106 MNC were collected and centrifuged at
500 × g for 10 min at 4°C. Supernatant was discarded
and cells were carefully resuspended in 60% (vol/vol) Percoll in
complete medium. Subsequently, 47.5 and 34% Percoll in complete medium
was layered upon the cell suspension. Cells were centrifuged for 40 min
at 1,700 × g. The low-density fraction representing
monocytes, as confirmed by flow cytometry, was collected and washed
twice with complete medium. Cells were adjusted to a concentration of
106 cells/ml, and cell viability as measured by
trypan blue exclusion always exceeded 95%.
Detection of IL-6-, TNF-
-, IL-10-, and IL-12-secreting
monocytes and mononuclear cells by ELISPOT assays.
To detect and
enumerate IL-6-, TNF-
-, IL-10-, and IL-12-secreting MNC and
monocytes, ELISPOT assays as originally described by Czerkinsky and
collaborators (7) were previously adapted to blood MNC
(19-21). Here we adapted ELISPOT assays to detect and
enumerate monocytes secreting cytokines. Microtiter plates with
nitrocellulose bottoms (Multiscreen-HA plates; Millipore, Mulsheim,
France) were coated for 2 h at 37°C with (per well) 100 µl of
MAb to human IL-6 (13A5), IL-10 (9-D7), IL-12p40 (13A5) (all from
Mabtech), or TNF-
(28401.11; R&D) diluted in sterile filtered
phosphate-buffered saline (PBS) (pH 7.4) to a concentration of 10 µg/ml. The IL-12p40 antibody applied in this study is capable of
detecting both the IL-12p40 subunit as well as the bioactive IL-12p70
(19). After removal of coating solutions by washing plates
six times with 200 µl of PBS and subsequent removal of excess PBS by
flicking, 200-µl aliquots containing 1 × 103, 2 × 103, 5 × 104, and 1 × 105
monocytes, respectively, were applied to individual wells in duplicate.
These cell numbers were found in kinetic studies to yield high numbers
of cells secreting the cytokines under study. As a positive control,
aliquots of monocytes were stimulated with lipopolysaccharide (LPS) at
a final concentration of 10 µg/ml. As a negative control, complete
medium was also added to wells in the absence of cells, or cells were
added to wells devoid of primary antibody. Plates were incubated at
37°C for 24 h in humidified air containing 5%
CO2 and then emptied and washed six times with 200 µl of PBS and subsequently dried by flicking. Aliquots (100 µl)
of a biotinylated MAb to human IL-6 (39C3), IL-10 (12G8), or IL-12p40
(39C3) (all from Mabtech) or a biotinylated polyclonal antibody to
TNF-
(R&D) diluted in filtered PBS to a concentration of 1 µg/ml
were added overnight at 4°C. Specificities of antibodies used were
checked in preliminary experiments. No cross-reactivity was found
between any of the tested antibodies (19, 20). Wells were
washed six times with 200 µl of PBS, and 100 µl of
streptavidin-alkaline phosphatase (Mabtech) diluted 1:1,000 in filtered
PBS was added subsequently for 1.5 h at room temperature. After
incubation, plates were emptied, washed 6 times with 200 µl of
TRIS-buffer, and stained with BCIP-NBT (Gibco) diluted in
Tris buffer. Spots were visible after 20 to 30 min. Plates were
emptied, washed with tap water, and dried. Immunospots, each considered
to represent a cell secreting IL-6, TNF-
, IL-10, or IL-12, were
counted with a dissection microscope under 25× magnification. The mean
values of duplicates were calculated. Results were presented as numbers of IL-6-, TNF-
-, IL-10-, or IL-12-secreting cells per
105 monocytes or MNC. No spots appeared in
control wells in which complete medium in the absence of cells or cells
in the absence of primary antibody was used. Variation between
duplicates was <10%.
Cytokine measurements by ELISA.
To detect cytokines secreted
by isolated monocytes, cells were diluted to a final concentration of
106 cells/ml in complete medium as found to be
optimal in preliminary experiments. In parallel, the same samples were
evaluated by ELISPOT assays. Cells for culture supernatants and ELISPOT
plates were incubated for 24 h at 37°C in humidified air
containing 5% CO2. The following day, cell-free
supernatants were collected, centrifuged, and stored at
70°C. Each
sample was tested in duplicate for IL-6, TNF-
, IL-10, and IL-12
production by ELISA with the same antibodies as those utilized in
ELISPOT assays according to the manufacturers' instructions. Optical
densities were measured using an ELISA reader. Cytokine concentrations
were calculated using standard curves that were performed for each
ELISA plate. The lowest detection limits were 8 pg/ml for TNF-
,
IL-12, and IL-10 and 12 pg/ml for IL-6. Measurements were repeated at
three different occasions.
Flow cytometry.
For surface staining, 100 µl of the cell
suspensions (at least 5 × 104 monocytes)
was incubated with a mixture of MAb conjugated with peridinin
chlorophyll protein, PE, and FITC for 30 min at 4°C in the dark. All
MAb were titrated in preliminary experiments. The cells were washed
twice with PBS containing 1% bovine serum albumin and centrifuged at
1,100 × g for 10 min. Cells were resuspended in 200 µl of 1% bovine serum albumin-PBS. Ten thousand events were
acquired in a Becton Dickinson FACScan flow cytometer. This instrument
was calibrated twice per month for fluorescence intensity (Calibrite;
Becton Dickinson). Control samples were stained with MAb of similar
isotype but irrelevant specificity.
Data analysis.
Flow cytometer data were processed using
CellQuest software (Becton Dickinson). To check the purity of the
monocytes obtained by density gradient centrifugation, each sample was
stained using anti-CD14 (monocyte-subpopulation), anti-CD3 (T cells),
and anti-CD19 (B cells) MAb. B- and T-cell contamination never exceeded
10%. In preliminary experiments, contamination by NK cells (CD56) and granulocytes (CD14
CD15+)
was checked. The percentages of NK cells and granulocytes never exceeded 0.25% of the gated population and were omitted during further
analyses. The phenotypes of the obtained monocytes and the
CD14-positive monocyte subpopulation were monitored with standard combinations of anti-CD14 versus anti-CD80, -CD86, -CD40, -HLA-DR, and
-HLA-ABC. Nonspecific isotype-matched IgGs conjugated to the same
fluorochromes were used as negative controls.
All materials and chemicals as listed above were endotoxin free
as tested by the manufacturers. All solutions, including the water used
to prepare the PBS and the medium, never contained concentrations or
endotoxin of <0.05 ng/ml as determined using E-toxate
Limulus amoebocyte assay (Gibco).
The study protocol was approved by the Ethical Committee of
Karolinska Institutet at Huddinge University Hospital, and informed consent was obtained from all healthy subjects.
Statistical analysis.
The Wilcoxon signed rank test was used
when paired samples of the same individual were compared. The
nonparametric Kruskal-Wallis analysis of variance test was used to
compare more than two groups simultaneously. Upon obtaining a
significant P value (P < 0.05) for
Kruskal-Wallis analysis of variance test, reflecting differences between one versus another group(s) under study, a multiple-comparisons test (25) was used to determine which groups under study
were differing. Spearman's rank test was used for correlations.
 |
RESULTS |
Analysis of purity and phenotype of isolated monocytes.
Purity
of the prepared monocyte population as examined by flow cytometry with
anti-CD3 and anti-CD19 MAb always exceeded 90% (mean purity, 95%).
Monocytes typically expressed high levels of CD14 (76% ± 16%),
HLA-ABC (90% ± 10%), HLA-DR (86% ± 16%), CD86 (82% ± 13%),
CD80 (7% ± 7%), and CD40 (21% ± 18%) (values are presented as
mean ± standard deviation [SD]) (Fig.
1). Occurrence of these markers and
morphological characteristics of monocytes (see Fig. 4A) is in
accordance with the role of monocytes/macrophages as antigen presenting
cells.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 1.
Representative example of flow cytometry plots and
histograms showing expression of CD3, CD19, CD14, HLA-ABC, HLA-DR,
CD80, CD86, and CD40 by monocytes obtained from a healthy control
prepared with Percoll density gradient separation (as described in
Materials and Methods). High percentages of monocytes expressing
and high levels of CD14 on monocyte cell surface as reflected by mean
fluorescence intensity were observed. Contamination of B
(CD19+) and T (CD3+) cells in monocyte
preparations did not exceed 10%. In concert with the characteristics
of professional antigen-presenting cells, monocytes expressed high
percentages and high levels of HLA-ABC, HLA-DR, and the costimulatory
molecule CD86 and moderate percentages and levels of the costimulatory
molecules CD40 and CD80 on monocyte cell surface. PerCP, peridinin
chlorophyll protein.
|
|
Analyses of monocyte recovery and yield.
To evaluate possible
loss of monocytes during Percoll density gradient centrifugation, two
experiments, each including five healthy controls, were performed. MNC
and high- and low-density fractions after Percoll separation were
collected and analyzed in parallel. MNC contained on an average 8%
monocytes, while the low-density fraction contained 98% monocytes at
separation by Percoll. In preliminary experiments using the blood of
five healthy controls, no significant loss of monocytes (<1%) during
preparation of MNC by Lymphoprep density gradient separation was
observed. We thus conclude that monocytes were isolated successfully.
Twenty milliliters of blood typically yielded 1.5 × 106 to 2 × 106 monocytes.
High levels of IL-6-, IL-10-, IL-12-, and TNF-
-secreting
monocytes were found in blood from healthy subjects and are augmented
by in vitro stimulation with LPS.
Monocytes are important
secretors of IL-6, TNF-
, IL-10, and IL-12 among MNC (19,
21). Therefore, IL-6-, TNF-
-, IL-10-, and IL-12-secreting
cells should be mainly confined to the low-density fraction,
representing monocytes, as obtained by Percoll separation. To test this
hypothesis, we performed ELISPOT assays on MNC, cells of the
high-density fraction, and cells from the low-density fraction, prepared from the same blood samples. In parallel, the proportions of
monocytes and B and T cells among MNC, high- and low-density fractions
of the same samples were also analyzed. Higher numbers of cells
secreting IL-6, IL-10, IL-12, and TNF-
were observed in the
low-density fraction, representing monocytes, compared to MNC of the
same sample (P < 0.01, P < 0.01, P < 0.05, and P < 0.01, respectively). Higher numbers of IL-6-, IL-10-, IL-12-, and
TNF-
-secreting cells in the monocyte fraction compared to the
high-density fraction, representing mainly B and T cells, were also
observed (P < 0.001, P < 0.01, P < 0.05, and P < 0.01, respectively). In parallel, we observed high proportions of monocytes, which were confined to the low-density fraction (Fig.
2). We therefore conclude that monocytes,
as obtained by Percoll separation, are confined to the low-density
fraction and contain high numbers of cells secreting IL-6, IL-10,
IL-12, and TNF-
.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Mean numbers and 1 SD (error bars) of IL-6 (A)-, TNF-
(B)-, IL-10 (C)-, and IL-12 (D)-secreting cells per 105
MNC, cells of the high-density fraction (MNC-M), and monocytes (M)
prepared by Percoll separation. The incubation time was chosen to be
24 h. Results are from study of 10 healthy subjects.
|
|
LPS is the principal component of the outer membrane of gram-negative
bacteria. Human monocytes are exquisitely sensitive to LPS and respond
by expressing many inflammatory cytokines. To evaluate the in vitro
effects of LPS on numbers of cytokine-secreting monocytes, monocytes
prepared from 25 healthy subjects were used. We observed high levels of
IL-6-, IL-10-, TNF-
(P < 0.0001 for all
comparisons)- and IL-12 (P < 0.001)-secreting
monocytes upon LPS stimulation compared to monocytes without such
stimulation. We thus conclude that monocytes prepared by Percoll
density gradient are capable of responding efficiently to exogenous
stimuli, e.g., LPS (Fig. 3).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 3.
Numbers of IL-6 (A)-, TNF- (B)-, IL-10 (C)-, and
IL-12 (D)-secreting monocytes from 25 healthy subjects after culture in
the absence (0) and in the presence of LPS. Arrows refer to median
values.
|
|
Evaluation of optimal incubation time for monocyte ELISPOT
assays.
Background staining of individual wells and levels of the
cytokines produced by the individual cells are highly dependent on
interactions between the individual cells, incubation period, etc.
Changes in assay conditions such as incubation period, therefore, are
likely to influence the assay results and ease of discriminating spot
from background staining considerably. Optimal incubation of ELISPOT
plates, therefore, should result in high numbers of clearly defined
dark spots against a light background. To determine the optimal
incubation time, monocytes were incubated for 24, 48, and 72 h.
Higher numbers of IL-6-, TNF-
-, IL-10-, and IL-12-secreting monocytes were observed after 24 h of incubation compared to
72 h of incubation (P < 0.05, P < 0.001, P < 0.001, and P < 0.01, respectively). Higher numbers of TNF-
(P < 0.05)
and IL-10 (P < 0.05) were also found after 24 h
compared to those after 48 h of incubation (Table
1). Spots were also easy to count after 24 h of incubation when size and clarity of spots were taken into consideration. In addition, background staining was minimal after 24 h of incubation (Fig. 4).
Therefore, a 24-h incubation period was chosen for all cytokines under
study for further experiments. In preliminary tests, incubation with
secondary antibody either for 2 h at room temperature or overnight
at 4°C resulted in similar numbers of monocytes secreting IL-6,
IL-10, IL-12, and TNF-
(data not shown). We chose incubation of
secondary antibody overnight at 4°C for further studies.

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 4.
Phenotypes of monocytes (Giemsa staining, ×400) as
prepared by Percoll density. (A) Monocytes are seen as large cells with
large indented nuclei. Also shown are representative examples of spots
representing IL-6 (B)-, TNF- (C)-, IL-10 (D)-, and IL-12
(E)-secreting monocytes. Spots each representing a cell
secreting cytokine appeared as clear dark-stained well-circumscribed
areas. Stained artifacts were easily distinguished from the spots of
secreted cytokine due to the size, stainability, and density of
contaminated objects.
|
|
Evaluation of optimal cell numbers for monocyte ELISPOT
assays.
To detect cells actively secreting cytokines by
ELISPOT assays, cells should be plated in a single cell layer. In
addition, the sensitivity of the assay is critically dependent on
numbers of cells employed per individual cell and frequency of
cytokine-secreting cells within the sample. Thus, for each cytokine
optimal cell numbers, i.e., the balance between application of a single
layer of cells versus high numbers of spots, should be determined. To determine cell concentrations yielding optimal numbers and quality of
spots, different numbers of monocytes were incubated per well. Based on
previous kinetic experiments using MNC (19, 20), we chose
the four concentrations 5,000, 2,000, 1,000, and 500 monocytes/200
µl/well for IL-6 and TNF-
. For IL-10, we chose the concentrations
50,000, 20,000, 10,000, and 5,000 monocytes/200 µl/well, and for
IL-12 we chose 100,000, 80,000, 60,000, and 40,000 monocytes/200
µl/well. No statistical differences in numbers of spots per
105 monocytes were observed for TNF-
or for
IL-6 different numbers of monocytes were applied. Spot size and spot
quality though were considered optimal for 2,000 monocytes/200
µl/well for IL-6 and for 1,000 monocytes/200 µl/well for TNF-
(Fig. 4 and 5). Numbers of
IL-10-secreting cells per 105 monocytes were
higher when 50,000 monocytes/200 µl/well were applied compared to
10,000 (P < 0.01) or 5,000 (P < 0.01)
monocytes/well. Since numbers of IL-10-secreting monocytes were highest
at the maximum concentration initially chosen, additional tests were performed. Eight healthy controls were studied, and cells were adjusted
to 100,000 and 50,000 monocytes/200 µl/well. No statistical differences were observed in numbers of spots per
105 monocytes between cell concentrations of
100,000 and 50,000 monocytes/200 µl/well. We considered the
application of 50,000 monocytes/200 µl/well for further studies. Also
the numbers of IL-12-secreting cells per 105
monocytes were higher when 100,000 monocytes/200 µl/well were applied
compared to 60,000 (P < 0.05) or 40,000 (P < 0.001) cells/200 µl/well. Since numbers of
IL-12-secreting monocytes were highest at the maximum concentration
chosen, monocytes prepared from eight healthy controls were studied.
Upon adjusting cells to 200,000 and 100,000 cells per well, no
differences in numbers of spots per 105 monocytes
of IL-12-secreting monocytes were observed between these cell
concentrations. We decided to select a concentration of 100,000 monocytes/200 µl/well to be used for further ELISPOT studies
(Fig. 5).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 5.
Mean numbers and one SD (error bars) of IL-6 (A)-,
TNF- (B)-, IL-10 (C)-, and IL-12 (D)-secreting cells per
105 monocytes from 18 healthy subjects examined by ELISPOT
assays. Different numbers of monocytes were incubated for 24 h. In
three different experiments, monocytes from three or four subjects were
examined with ELISPOT assays. Four different cell numbers per well for
IL-6 and TNF- and five different cell numbers per well for IL-10 and
IL-12, as displayed on the x axis, were tested. Wells
without cells were used as a negative control. Cell numbers were
defined as optimal depending on the size, clarity, and yield of spots
obtained. To enumerate monocytes secreting IL-6, incubation of 2,000 monocytes per well was considered to be optimal, for TNF- 1,000 monocytes per well was considered optimal, for IL-10 50,000 monocytes
per well was considered optimal, and for IL-12 100,000 monocytes per
well was considered optimal.
|
|
Interassay variability for monocyte ELISPOT assays.
To test
interassay variability of monocyte ELISPOT assays, monocytes of five
healthy subjects were prepared and applied to ELISPOT assays at two
different occasions. Numbers of monocytes secreting IL-6 or
IL-12 varied less than 10%, and numbers of monocytes secreting TNF-
or IL-10 varied less than 15% between the two samplings (Fig.
6).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Numbers of IL-6 (A)-, TNF- (B)-, IL-10 (C)-, and
IL-12 (D)-secreting cells per 105 monocytes from five
healthy subjects (HC) sampled on two occasions. The variation in
numbers of IL-6- and IL-12-secreting monocytes was less than 10% and
less than 15% for IL-10 and TNF- . Black bars represent first
sampling.
|
|
Detection of monocytes producing and secreting cytokine by ELISPOT
assays and ELISA.
To compare different techniques for cytokine
detection, monocytes from 18 healthy donors were prepared and analyzed
for cytokine production by ELISPOT assays and ELISA in parallel. Using
ELISPOT assays, cytokine-secreting monocytes could be detected in each specimen. High numbers of TNF-
- and IL-6-secreting cells were observed in healthy donors; IL-12- and IL-10-secreting monocytes were
detected at a much lower frequency. Among healthy subjects, 5% ± 1%
of the monocytes secreted IL-6, 7% ± 3% secreted TNF-
, 0.2% ± 0.1% secreted IL-10, and 0.1% ± 0.1% secreted IL-12 (Table 2). Variation between duplicates was
<10% in ELISPOT assays. Secreted cytokines could also be detected by
ELISA in all samples. Variation between duplicates for ELISA was 17%
for TNF-
, 28% for IL-6, and 17% for IL-10; this variation between
duplicates was much higher (P < 0.05, P < 0.001, and P < 0.0001, respectively) compared to ELISPOT assays. Variation between duplicates
was similar for levels of IL-12 (10%) as measured by ELISA compared to
numbers of IL-12-secreting monocytes by ELISPOT. Correlation
between numbers of cytokine-secreting cells as measured by ELISPOT and
levels of secreted cytokines by ELISA were observed for monocytes
secreting TNF-
(r = 0.7; P < 0.01),
IL-6 (r = 0.6; P < 0.01), and IL-12 (r = 0.5; P < 0.05) (Table 2).
 |
DISCUSSION |
The detection of cytokines is hampered by their biological
properties, e.g., local secretion, rapid uptake and utilization, and
short half-life (13). These properties have led to the
development of numerous tools to detect transcribed, translated, or
secreted cytokines. The usefulness of methods detecting either
transcribed or translated proteins is limited since cytokines carry out
their functions mainly after secretion of the protein. Therefore,
detection of cytokines before their secretion might not be a reliable
reflection of the released effector cytokine. Alternatively, secreted
cytokines may be measured in body fluids using ELISA. The presence of
cytokine binding proteins in serum might reduce the cytokine levels in biological fluids, making results obtained by ELISA less
representative. To date, the biological relevance of determining
absolute quantities of cytokines has not been addressed. Cytokines may
exert their influence with extremely variable levels of biologically
active protein. Assessment of cytokine-secreting cells by ELISPOT
circumvents most of these problems (8) and offers the
advantage of close protein-capture antibody proximity and strong
electrostatic interactions that circumvent paracrine and autocrine
cytokine uptake of the cytokine (24). Thus, ELISPOT assay
allows the detection of well-defined spots that clearly represent
numbers of cytokine-secreting cells present in the circulation. In
addition, high specificity combined with high sensitivity makes ELISPOT
assays attractive tools in the evaluation of cytokines. A drawback of
ELISPOT assays is the difficulty of establishing the assays for new
cytokines due to scarce availability of suitable antibody pairs.
In the present study, ELISPOT assays were adapted to detect and
enumerate monocytes secreting selected cytokines. To obtain high yields
of monocytes with high purity, we applied a modified two-step density
gradient method (26). Many other methods of separating
monocytes either lack the ability to yield sufficient numbers of cells
of high purity or require expensive equipment and extensive separation
time. Alternatively, pure populations of CD14+
monocytes are obtained by different sorting strategies. However, since
CD14
monocytes represent up to 25% of
the monocytes in healthy donors, the CD14+
population might not represent the properties of the whole monocyte population. Density gradient separation of monocytes as used in the
present study was relatively quick (less than 4 h) and yielded monocytes with a purity of >90%. Most of the monocytes were recovered by Percoll separation, leading us to conclude that no major selection of a subpopulation of monocytes occurred during separation. Yields obtained by this method were typically 1.5 × 106 to 2.0 × 106
monocytes per 20 ml of blood.
We adapted ELISPOT assays to detect monocytes secreting IL-6, TNF-
,
IL-10, and IL-12. These cytokines are able to shift the immune response
either towards a Th1 type via IL-12, thereby facilitating the
production of cytokines such as TNF-
and IL-6, or to promote the
production of Th2-related cytokines such as IL-4 by IL-10 (15). A tight regulation of these four cytokines,
therefore, keeps the balance and decides whether Th1 or Th2 will
predominate in immune reactions (5, 9, 22, 23). LPS is the
principal component of the outer membrane of gram-negative bacteria.
Humans have evolved to detect low levels of LPS to combat infections. Monocytes orchestrate the innate immunity response to LPS by expressing a variety of inflammatory cytokines that include TNF-
(12). In the present study, we evaluated the in vitro
stimulatory capacity of LPS on numbers of IL-6-, IL-10-, IL-12-, and
TNF-
-secreting monocytes. We observed augmented numbers of monocytes
secreting all of the cytokines under study upon LPS stimulation. The
present findings thus may make ELISPOT assays a useful tool in studying changes in levels of cytokine secreting monocytes upon stimulation with
bacterial or other antigens.
The optimal time for incubation was found to be 24 h, and the
optimal numbers of cells to be applied were found to be 2,000 cells/200
µl/well for IL-6, 1,000 cells/200 µl/well for TNF-
, 50,000 cells/200 µl/well for IL-10, and 100,000 cells/200 µl/well for
IL-12. The numbers of spots detectable as well as their quality constituted the basis for deciding on the optimal incubation period and
optimal cell numbers. The interassay variability for monocyte ELISPOT
assays was less than 15%.
Upon comparison of different techniques to detect cytokine production
by monocytes, we observed correlations between ELISPOT and ELISA
results for the cytokines TNF-
, IL-6, and IL-12. The high
intra-assay variability observed with ELISA compared to ELISPOT as well
as possible reuptake of cytokine by monocytes (8) may make
this method less suitable for detection of secreted cytokines by blood monocytes.
In conclusion, by applying ELISPOT assays we enumerated monocytes
secreting IL-6, TNF-
, IL-10, and IL-12. Since ELISPOT assays are
highly sensitive and specific tools in measurement of cytokines, ELISPOT analysis of cytokine-secreting cells provides a very useful tool in investigating monocyte properties.
 |
ACKNOWLEDGMENTS |
We thank Staffan Pauli for valuable scientific discussions about
the manuscript and for providing recombinant standards for ELISA. This
study was supported by grants from the Swedish Medical Research Council
and the Swedish Medical Association and funds from the Karolinska Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Mathilde
Kouwenhoven, Department of Neurology, Huddinge University Hospital,
SE-141 86 Stockholm, Sweden. Phone: 46-8-5858 2277. Fax: 46-8-5858 7080. E-mail: mathilde.kouwenhoven{at}neurotec.ki.se.
 |
REFERENCES |
| 1.
|
Al-Janadi, M.,
S. Al-Balla,
A. Al-Dalaan, and S. Raziuddi.
1993.
Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases.
J. Clin. Immunol.
13:58-67[CrossRef][Medline].
|
| 2.
|
Barnes, A.
1998.
Measurement of serum cytokines.
Lancet
352:324-325[Medline].
|
| 3.
|
Becher, B.,
M. Blain,
P. S. Giacomini, and J. P. Antel.
1999.
Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12.
J. Immunol.
162:684-688[Abstract/Free Full Text].
|
| 4.
|
Betjes, M. G. H.,
C. E. G. Havenith,
A. A. Van de Loosdrecht, and R. J. H. Beelen.
1994.
Methods for studying immuno-effector functions and antigen presenting activity of human macrophages.
J. Immunol. Methods
174:215-222[CrossRef][Medline].
|
| 5.
|
Bruck, W.,
P. Porada,
S. Poser,
P. Rieckmann,
F. Hanefeld,
H. A. Kretzschmar, and H. Lassmann.
1995.
Monocyte/macrophage differentiation in early multiple sclerosis lesions.
Ann. Neurol.
38:788-796[CrossRef][Medline].
|
| 6.
|
Coligan, J. E.,
A. M. Kruisbeek,
D. H. Margulies,
E. M. Shevach, and W. Strober (ed.).
1994.
Current protocols in immunology, vol. 2. , p. 7.6.1-7.6.8.
John Wiley & Sons, New York, N.Y.
|
| 7.
|
Czerkinsky, C. C.,
G. Andersson,
H.-P. Ekre,
L.-Å. Nilsson,
L. Klareskog, and Ö. Ouchterlony.
1988.
Reverse ELISPOT assay for clinical analysis of cytokine production. I. Enumeration of gamma-interferon secreting cells.
J. Immunol. Methods
110:29-36[CrossRef][Medline].
|
| 8.
|
Ewen, C., and M. E. Baca-Estrada.
2001.
Evaluation of interleukin-4 concentration by ELISA is influenced by the consumption of IL-4 by cultured cells.
J. Interferon Cytokine Res.
21:39-43[Medline].
|
| 9.
|
Fagiolo, U.,
A. Cossarizza,
E. Scala,
E. Fanales-Belasio,
C. Ortolani,
E. Cozzi,
D. Monti,
C. Franchesi, and R. Paganelli.
1993.
Increased cytokine production in mononuclear cells of healthy elderly people.
Eur. J. Immunol.
23:2375-2378[Medline].
|
| 10.
|
Fiorentino, D. F.,
A. Zlotnik,
T. R. Mosmann,
M. Howard, and A. O'Garra.
1991.
IL-10 inhibits cytokine production by activated macrophages.
J. Immunol.
147:3815-3822[Abstract].
|
| 11.
|
Graziani-Bowering, G. M.,
J. M. Graham, and L. G. Filion.
1997.
A quick, easy, and inexpensive method for the isolation of human peripheral blood monocytes.
J. Immunol. Methods
207:157-168[CrossRef][Medline].
|
| 12.
|
Guha, M., and N. Mackman.
2001.
LPS induction of gene expression in human monocytes.
Cell. Signal.
13:85-94[CrossRef][Medline].
|
| 13.
|
Hagiwara, E.,
F. Abbasi,
G. Mor,
Y. Ishigatsubo, and D. M. Klinman.
1995.
Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN and TNF- in human peripheral blood.
Cytokine
7:815-822[CrossRef][Medline].
|
| 14.
|
Kouwenhoven, M.,
N. Teleshova,
V. Özenci,
R. Press, and H. Link.
2001.
Monocytes in multiple sclerosis: phenotype and cytokine profile.
J. Neuroimmunol.
112:197-205[CrossRef][Medline].
|
| 15.
|
Ma, X.,
A. D'Andrea,
M. Kubin,
M. Aste-Amezaga,
A. Sartori,
J. Monteiro,
L. Showe,
M. Wysocka, and G. Trinchieri.
1995.
Production of interleukin- 12.
Res. Immunol.
146:432-438[CrossRef][Medline].
|
| 16.
|
Marchant, A.,
J. Deviere,
B. Byle,
D. De Groote,
J. Vincent, and M. Goldman.
1994.
Interleukin-10 production during septicaemia.
Lancet
343:707[CrossRef][Medline].
|
| 17.
|
Matusevicius, D.,
P. Kivisäkk,
V. Navikas,
M. Söderström,
S. Fredrikson, and H. Link.
1998.
Interleukin-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis.
Scand. J. Immunol.
47:582-590[CrossRef][Medline].
|
| 18.
|
Nathan, C. F.
1987.
Secretory products of macrophages.
J. Clin. Investig.
79:319-326.
|
| 19.
|
Özenci, V.,
M. Kouwenhoven,
R. Press,
H. Link, and Y. M. Huang.
2000.
IL-12 ELISPOT assays to detect and enumerate IL-12 secreting cells.
Cytokine
12:1218-1224[CrossRef][Medline].
|
| 20.
|
Özenci, V.,
M. Kouwenhoven,
Y.-M. Huang,
P. Kivisäkk, and H. Link.
2000.
Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha and IL-10-secreting blood cells that is corrected by interferon-beta treatment.
Clin. Exp. Immunol.
120:147-153[CrossRef][Medline].
|
| 21.
|
Press, R.,
G. Deretzi,
L. P. Zou,
J. Zhu,
P. Fredman,
J. Lycke, and H. Link.
2001.
IL-10 and IFN-gamma in Guillain-Barre syndrome. Network Members of the Swedish Epidemiological Study Group.
J. Neuroimmunol.
112:129-138[CrossRef][Medline].
|
| 22.
|
Roubenoff, R.,
T. B. Harris,
L. W. Abad,
P. W. F. Wilson,
G. E. Dallal, and C. A. Dinarello.
1998.
Monocyte cytokine production in an elderly population: effect of age and inflammation.
J. Gerontol.
53:M20-M26.
|
| 23.
|
Rudick, R. A., and R. M. Ransohoff.
1992.
Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity.
Arch. Neurol.
49:265-270[Abstract].
|
| 24.
|
Shirai, A.,
K. Holmes, and D. M. Klinman.
1993.
Detection and quantitation of cells secreting IL-6 under physiological conditions in BALB/c mice.
J. Immunol.
150:793-799[Abstract].
|
| 25.
|
Siegel, S., and N. J. Castellan, Jr.
1988.
Nonparametric statistics for the behavioural sciences, 2nd ed., p. 213-214.
McGraw-Hill International Editions, New York, N.Y.
|
| 26.
|
Snijders, A.,
T. C. Van der Pouw Kraan,
M. Engel,
J. Wormmeester,
P. Widjaja,
I. M. Zonneveld,
J. D. Bos, and M. L. Kapsenberg.
1998.
Enhanced prostaglandin E2 production by monocytes in atopic dermatitis (AD) is not accompanied by enhanced production of IL-6, IL-10 or IL-12.
Clin. Exp. Immunol.
111:472-476[CrossRef][Medline].
|
| 27.
|
Tanguay, S., and J. Killion.
1994.
Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells.
Lymphokine Cytokine Res.
13:259-263[Medline].
|
| 28.
|
Van Boxel-Dezaire, A. H. H.,
S. C. J. Hoff,
B. W. Van Oosten,
C. L. Verweij,
A. M. Dräger,
H. J. Ader,
J. C. Van Houwelingen,
F. Barkhof,
C. H. Polman, and L. Nagelkerken.
1999.
Decreased interleukin-10 and increased interleukin p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis.
Ann. Neurol.
45:695-703[CrossRef][Medline].
|
| 29.
|
Williams, M. A.,
A. C. Newland, and S. M. Kelsey.
1999.
The potential for monocyte-mediated immunotherapy during infection and malignancy. Part I: apoptosis induction and cytotoxic mechanisms.
Leuk. Lymphoma
34:1-23[Medline].
|
| 30.
|
Williams, M. A.,
C. J. Roades,
A. C. Newland, and S. M. Kelsey.
1999.
The potential for monocyte-mediated immunotherapy during infection and malignancy. Part II: in vivo activation by exogenous cytokines and clinical applications.
Leuk. Lymphoma
34:207-230[Medline].
|
Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1248-1257, Vol. 8, No. 6
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.6.1248-1257.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kim, M. P., Zhou, M., Wahl, L. M.
(2005). Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J. Leukoc. Biol.
78: 195-201
[Abstract]
[Full Text]